Executive Summary
Japanese real-world data from the CURRENT AS Registry-2 shows TAVR and SAVR deliver comparable 3-year outcomes in low-risk severe AS patients (19.5% vs 17.4% composite of death, disabling stroke, or HF hospitalization; adjusted HR 1.05) — confirming transcatheter therapy holds its own outside RCT settings without resolving the durability question that keeps ACC/AHA 2020 favoring SAVR in patients under 65. A separate French cohort of 976 patients aged 75+ found frailty by the Rockwood Clinical Frailty Scale was the only geriatric predictor of 5-year mortality after TAVR (HR 1.12; 46% overall 5-year mortality), and a PASCAL M-TEER series in patients ≥85 reported outcomes indistinguishable from younger patients — evidence that both age extremes need better selection tools, not blanket age cutoffs. The DEDICATE-informed ESC 2025 shift to TAVI-preferred at age ≥70 gains support from Japan but not resolution.
- Japanese propensity-matched registry (N=162/group) shows no TAVR vs SAVR difference at 3 years in low-risk severe AS (CVIT).
- Frailty (Rockwood CFS) independently predicts 5-year mortality after TAVR in patients ≥75; mortality rose from 38% (robust) to 55% (severely frail) (JAGS).
- PASCAL M-TEER in 71 patients aged ≥85 delivered zero 30-day mortality and residual MR profiles matching younger patients (CCI).
- Incidental non-cardiac CT findings on pre-TAVR scans independently predict mortality, per new imaging analysis (Cardiovascular Business).
- Women hold only 7.0% of steering committee seats and 14.0% of senior authorships in high-impact structural heart trials over 15 years, with no significant improvement (JACC Advances).
What to watch: Edwards reports Q3 earnings October 29 with a $0.74 EPS estimate — the first read on whether TAVR volume growth is decelerating as ESC 2025's age-70 threshold reshapes European practice.
Aortic Valve (TAVR/TAVI)
The CURRENT AS Registry-2 matched 162 low-risk patients per arm and found no difference in the composite of death, disabling stroke, or HF hospitalization at 3 years (19.5% TAVR vs 17.4% SAVR; adjusted HR 1.05, 95% CI 0.50–2.20). The limitations are the story: non-randomized, single-country, 3-year follow-up only. Three years is exactly the window where TAVR and SAVR always look similar. The relevant comparison for a Japanese patient in their late 60s is 10–15 year structural valve deterioration, and this registry cannot speak to it. ACC/AHA 2020 still recommends SAVR for patients under 65 on durability grounds; ESC 2025 pushed that threshold to under 70, citing DEDICATE and PARTNER 3/Evolut 5-year data. This registry adjudicates neither.
The Nantes single-center analysis of 976 TAVR patients ≥75 delivers a more actionable finding: after multivariate adjustment, only Rockwood CFS predicted 5-year mortality (HR 1.12 per point). Nutritional status, cognition, and comorbidity indices dropped out. Five-year mortality was 46% overall — a figure that should temper enthusiasm for TAVR in frail octogenarians and reinforce that ESC 2025's "TAVI at 70" recommendation assumes reasonable life expectancy. Adding a 2-minute frailty scale to the pre-procedural workup outperforms most of what the Heart Team currently deliberates. Cardiovascular Business flagged separately that incidental CT findings on planning scans add prognostic weight — another signal that mortality in this population is driven by non-valvular biology.
A two-case series of Impella 5.5 as bridge therapy for acute severe bioprosthetic AR with cardiogenic shock is worth flagging: transvalvular support in severe AR has traditionally been contraindicated, but successful bridging to valve-in-valve TAVR and redo SAVR suggests the door is opening. A 3-patient full-body embolic protection series during TAVR in patients with intracardiac thrombus is an early-signal case report only — feasibility is not efficacy.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER extends safely into the ninth decade — but the trial evidence base still does not. The German single-center PASCAL series compared 71 patients aged ≥85 (mean 87.0, STS-Score 6.4) with 304 younger patients and found no leaflet injury, no single leaflet detachment, and no device-related complications in either group. Residual MR at 90 days was equivalent; 30-day mortality was zero in the older cohort; overall mortality at median 430 days was 5.6% vs 7.6% (p=0.76). Retrospective, single-center, N=375, no core lab — but the direction is consistent. Patients in this age range were systematically excluded from COAPT and RESHAPE-HF2, which underpin the ESC 2025 Class I recommendation for TEER in ventricular SMR and the ACC/AHA 2020 Class IIa. Real-world data of this kind gradually erodes the age exclusion; it does not substitute for RCT inclusion.
The surgical standard remains unchanged: in primary MR, surgical repair with a durable result is Class I in both ACC/AHA 2020 and ESC 2025 and is the preferred pathway for any patient with a reasonable operative window. TEER is Class IIa for high-risk symptomatic PMR in both guidelines. The German series enrolled patients with a mean STS above the threshold that would direct them to TEER regardless of age — this is not evidence for TEER in 85-year-olds with moderate MR and repairable anatomy.
A case report of posteromedial papillary muscle head rupture one week after cumulative liposomal doxorubicin (534 mg) in a 78-year-old with preserved EF and prior lung radiation is a hypothesis-generating "two-hit" observation worth noting for cardio-oncology imaging protocols.
Tricuspid Valve (TriClip, TTVR)
A comprehensive Ebstein anomaly imaging and therapeutics review reinforces that cone reconstruction remains the preferred surgical repair and that dedicated transcatheter TR replacement in this population remains investigational. The ESC 2025 Class IIa recommendation for transcatheter TV treatment — derived from TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — explicitly does not extend to congenital tricuspid disease. Ebstein patients require reference-center surgical evaluation. ACC/AHA 2020 does not address transcatheter TR therapy at all; that is the guideline gap most likely to close in the next update cycle as EVOQUE and TriClip real-world registries mature.
Surgical vs. Transcatheter Comparisons
The CURRENT AS Registry-2 is the day's only direct comparison — a null result at 3 years in low-risk AS. Read alongside the Nantes frailty analysis, the picture sharpens: in the 65–70 age zone where ACC/AHA and ESC disagree on modality, what determines outcomes is patient selection — frailty, life expectancy, coronary anatomy, and future reintervention planning — not the choice of TAVR versus SAVR per se. The "looming wave" editorial on bioprosthetic TAV failure makes the stakes concrete: TAV-in-TAV feasibility, coronary access preservation, and neo-skirt height are index-procedure decisions with 10-year consequences. A companion piece on aortic annular enlargement in the valve-in-valve era makes the surgical case that annulus size at the index SAVR determines the entire downstream reintervention pathway.
Device & Technology
A 3-patient experience with a full-body embolic protection device during TAVR in patients with high embolic risk (aortic valve thrombus, LVOT mass, persistent LA thrombus) reports successful deployment and retrieval, no neurologic events at 30 days, and macroscopic debris capture in 2 of 3 cases. This is feasibility only. Whether Sentinel or any successor device reduces disabling stroke remains unanswered; expanding protection distally does not resolve that question.
An EMR retrieval study in 1,426 TAVR patients found that a zero-shot large language model outperformed ICD-based cardiovascular event ascertainment for stroke and composite MACE (AUC 0.915 and 0.862 vs lower for ICD). Retrospective validation only, but it is the most credible signal to date that LLMs may replace manual adjudication for registry endpoints — with direct implications for how post-market TAVR surveillance is conducted.
Industry & Market
Medtronic veteran Bill Shields is now CEO of Versa Vascular, a valve disease startup — the latest example of talent flowing from established transcatheter platforms into early-stage device companies, per Fierce Biotech. Structural heart remains a magnet for venture capital despite Boston Scientific's 32% 6-month drawdown.
Financial Analysis
Edwards has climbed 14% over the past 3 months per The Globe and Mail, riding TAVR volume growth and TriClip momentum, and now trades at 55x trailing / 27x forward earnings. That multiple assumes ESC 2025's age-70 threshold expands the addressable European TAVR pool without accelerating durability concerns in the under-70 cohort — a bet on execution over evidence. Boston Scientific's 32% 6-month decline reflects market concerns about Watchman and PFA competitive positioning, not structural heart specifically. The rising wave of bioprosthetic valve failure creates a redo-TAVR/TAV-explant tailwind for Edwards and Medtronic that is not yet priced.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $92.56, -0.53% on day; +17.99% over 6 months; range $76.33–$96.29
- Market cap $53.3B; P/E trailing 55.1, forward 27.4; beta 0.85
- Analyst target $100.96 (26 analysts); consensus buy
- Next earnings 2026-10-29 (EPS est $0.74, revenue est $1.68B)
- An insider CVP sale of $56,966 was reported — small, routine.
Medtronic (MDT)
- Close $90.58, -0.20% on day; -4.43% over 6 months; range $72.65–$97.30
- Market cap $115.9B; P/E trailing 24.4, forward 14.1; beta 0.57
- Analyst target $98.44 (25 analysts); consensus buy
- Next earnings 2026-09-01 (EPS est $1.39, revenue est $9.55B)
- Evolut share continues to hold in the low-risk segment; the ESC 2025 age-70 shift is a European tailwind.
Abbott (ABT)
- Close $111.27, +0.32% on day; +0.45% over 6 months; range $81.39–$115.27
- Market cap $193.8B; P/E trailing 35.9, forward 18.4; beta 0.58
- Analyst target $119.40 (25 analysts); consensus buy
- Next earnings 2026-10-14 (EPS est $1.42, revenue est $12.99B)
- Recent 8-K filing on file; no material structural heart disclosure.
Boston Scientific (BSX)
- Close $51.69, +0.53% on day; -32.25% over 6 months; range $42.20–$76.87
- Market cap $74.9B; P/E trailing 20.8, forward 15.0; beta 0.57
- Analyst target $62.69 (29 analysts); consensus buy
- Next earnings 2026-10-28 (EPS est $0.81, revenue est $5.26B)
- ACURATE Prime and Sentinel remain the structural heart franchise; drawdown driven by broader portfolio concerns.
Anteris Technologies (AVR.AX)
- Close A$12.10, -1.87% on day; +51.06% over 6 months; range A$7.13–A$15.47
- Market cap A$1.2B; forward P/E -5.58; beta 0.73
- Single analyst target A$13.00; hold
- DurAVR THV early clinical data continues to drive the equity story; commercial pathway still years out.
Sector view: Edwards' 18% run reflects TAVR volume durability and TriClip momentum, but the 55x trailing multiple bakes in continued expansion of transcatheter indications — including bicuspid AV and asymptomatic severe AS, both of which remain guideline-restricted. Medtronic looks fundamentally cheap at 14x forward, with the Evolut franchise underappreciated. Boston Scientific's structural heart franchise is smaller and the 32% drawdown reflects broader concerns rather than valve-specific weakness.
Clinical Trial Updates
The JACC Advances systematic review of 88 interventional structural heart trials from 2010–2025 found women held 7.0% of steering committee seats, chaired 12.0% of committees, and were senior authors on 14.0% of publications, with no significant improvement over 15 years. The accompanying Mehran/Itchhaporia/Parikh editorial calls for deliberate policy intervention. This is the trial ecosystem generating the evidence base for every recommendation in ACC/AHA 2020 and ESC 2025. Trial leadership representation is not cosmetic — it shapes enrollment criteria, endpoint selection, and subgroup analyses, all of which have direct downstream effects on how sex-specific structural heart outcomes are understood.
Social & Conference Highlights
David Taggart, the Oxford cardiovascular surgeon whose bilateral internal thoracic artery advocacy and skepticism of underpowered PCI-vs-CABG comparisons defined a generation of surgical evidence discourse, died at 69. Taggart's editorial voice — refusing to let the interventional field claim equipoise on incomplete data — is directly relevant to how the valve community should read TAVR-vs-SAVR long-term durability signals.
What next: Watch for 5- and 7-year DEDICATE follow-up, EARLY TAVR subgroup analyses stratified by frailty, and the first substantial real-world PASCAL data in patients ≥85 to move beyond single-center series. The next ACC/AHA update needs to reconcile ESC 2025's age-70 shift with the durability signals that will emerge from PARTNER 3 and Evolut Low Risk 10-year data — likely arriving in 2027–2028.